With aging, fibrinogen transcytosed via caveolin-1 into the perivascular space, exacerbating Aβ buildup. Elevated fibrinogen disrupted aquaporin-4 function. Depleting fibrinogen rescued CAA, ...

Artificial intelligence learns to recognize subtle biochemical features of γ-secretase substrates. Screening potential transmembrane proteins identifies 250 substrates, including 160 novel ones. These ...

Scientists trained three machine-learning algorithms to find variants that distinguish AD cases from controls among more than 40,000 European AD Biobank samples. ML found as many genome-wide ...

Eight months after Eli Lilly reported that a more gradual titration for donanemab nearly halved the risk of ARIA-E, the U.S. Food and Drug Administration has given the modification the green light.

Discover a comprehensive list of brain banks worldwide, facilitating Alzheimer's and Parkinson's research on Alzforum.

Award Up to ten McKnight Scholars will be selected to receive three years of support, beginning June 1, 2026. The total award is $225,000 paid in equal installments of $75,000 in 2026, 2027, and 2028.

Award The prize is presented for outstanding research performed by the applicant as described in a 1,000-word essay. The Grand Prize winner will be awarded a cash prize of USD 25,000 and will be ...

18 Feb 2022 Behold the deluge. The Centers for Medicare and Medicaid Services’ (CMS) proposal last month to restrict Aduhelm coverage to clinical trials stirred up such strong feelings on both sides ...

23 Jan 2020 Aβ oligomers may set off tau phosphorylation by hijacking the adrenergic system, according to a study published January 15 in Science Translational Medicine. Researchers led by Qin Wang at ...

Researchers genetically engineered human iPSC-microglia to deliver neprilysin when the cells are near amyloid plaques. Both local injection and brain-wide engraftment of neprilysin-secreting microglia ...

Two Phase 3 trials testing elenbecestat in early AD are stopping. The trials were halted due to safety concerns. Elenbecestat was the last active BACE inhibitor trial for AD.

In human stem-cell-derived neurons, the Swedish mutation boosted synapses. BACE inhibition, or APP deletion, reduced synapse numbers. Aβ monomer peptides fueled the synaptic boost.